MicroRNA‑92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus‑16 E6 
in cervical cancer cells

Yu,Yu; Zhang,Yao; Zhang,Shulan

doi:10.3892/ol.2013.1404

MicroRNA‑92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus‑16 E6 in cervical cancer cells

Authors:
- Yu Yu
- Yao Zhang
- Shulan Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: June 17, 2013 https://doi.org/10.3892/ol.2013.1404
Pages: 468-474

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑92 is overexpressed in a number of tumors and has been proven to negatively regulate a number of tumor suppressor genes, including phosphatase and tensin homologue (PTEN). However, its function and molecular mechanism(s) of action in squamous cervical carcinoma (SCCs) have not been well described. Furthermore, the correlation between miR‑92 and human papillomavirus (HPV)‑16 E6 has not been studied. In the present study, miR‑92 expression levels were quantified using quantitative PCR (qPCR) in cervical cancer tissues, normal cervical tissues and cervical cancer cell lines. SiHa cells were transfected with either miR‑92‑mimics, anti‑miR‑92 or negative controls. C33A cells were stably transfected with pEGFP‑N1‑16E6 and pEGFP‑N1‑neo plasmids. The levels of PTEN protein expression in the transfected SiHa and C33A cells were evaluated using western blot analysis. The effects of miR‑92 were detected using cell counting kit (CCK)‑8 and Transwell assays. HPV16 E6 siRNA was used to detect the effectiveness of the E6 protein on miR‑92 in the SiHa and C33A cells. miR‑92 was highly‑expressed in the human cervical cancer tissues compared with the normal tissues. In the HPV16‑positive cervical cancer tissues, the expression of miR‑92 was higher compared with the HPV16‑negative cervical cancer tissues. HPV16 E6 upregulated miR‑92 expression in the SiHa‑ and C33A‑pEGFP‑N1‑16E6 cells. The upregulation of miR‑92 promoted cell growth and invasion in the SiHa cells. PTEN protein expression was decreased in the SiHa cells that were transfected with the miR‑92 mimic. The data indicated that miR‑92 may increase the migration and invasion of SiHa cells, partially through the downregulation of PTEN protein expression. HPV16 E6 was identified to upregulate miR‑92 expression.

View Figures

View References

1.	Bosch FX and de Sanjosé S: Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 31:3–13. 2003. View Article : Google Scholar : PubMed/NCBI
2.	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
3.	Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 8:23–36. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Rao PH, Houldsworth J, Dyomina K, et al: Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 92:234–240. 1998.PubMed/NCBI
7.	Ota A, Tagawa H, Karnan S, et al: Identification and characterization of a novel gene, C13orf25, as a target for 13q31–q32 amplification in malignant lymphoma. Cancer Res. 64:3087–3095. 2004.
8.	Tagawa H and Seto M: A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia. 19:2013–2016. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Olive V, Bennett MJ, Walker JC, Ma C, et al: miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23:2839–2849. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Zhang X, Yu H, Lou JR, Zheng J, et al: MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 286:1429–1435. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Cho WC, Chow AS and Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Eades G, Yang M, Yao Y, Zhang Y and Zhou Q: miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem. 286:40725–40733. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al: Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 9:405–414. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Bonneau D and Longy M: Mutations of the human PTEN gene. Hum Mutat. 16:109–122. 2000. View Article : Google Scholar : PubMed/NCBI
15.	Petrocelli T and Slingerland JM: PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res. 3:356–360. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Byun D, Cho K, Ryu B, et al: Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer. 104:318–327. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar
18.	Shigoka M, Tsuchida A, Matsudo T, et al: Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 60:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Al-Nakhle H, Burns PA, Cummings M, et al: Estrogen receptor (beta)1 expression is regulated by miR-92 in breast cancer. Cancer Res. 70:4778–4784. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
21.	Li B, Hu Y, Ye F, Li Y, Lv W and Xie X: Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 20:597–604. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, et al: p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol. 4:2292008. View Article : Google Scholar : PubMed/NCBI
23.	Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu W, Wan X, Ma D and Xie X: Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Rao Q, Shen Q, Zhou H, Peng Y, Li J and Lin Z: Aberrant microRNA expression in human cervical carcinomas. Med Oncol. 29:1242–1248. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Au Yeung CL, Tsang TY, Yau PL and Kwok TT: Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene. 30:2401–2410. 2011.PubMed/NCBI
26.	Zheng ZM: Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int J Biol Sci. 6:730–755. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Narisawa-Saito M and Kiyono T: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
28.	McLaughlin-Drubin ME and Münger K: The human papillomavirus E7 oncoprotein. Virology. 384:335–344. 2009. View Article : Google Scholar : PubMed/NCBI